Dravet syndrome

On September 26, a marijuana-based childhood epilepsy drug took a step closer to winning approval when its maker announced promising phase 3 clinical trial results. [1]
Justin Gover, CEO of the British biotech company GW Pharmaceuticals, said that the children participating in the trial had previously tried 10 other anti-epileptic drugs. Despite using the medication, the young participants still experienced 3 seizures a day, approximately 90 a month. Said Gover:

A 120-patient trial showed patients taking cannabis-based Epidiolex were able to reduce their convulsive seizures by 39 percent.
The post New Cannabis Drug Able to Reduce Seizures by 39% for Some Epilepsy Patients appeared first on The Anti-Media.

What would you do if your child had a serious form of epilepsy that was resistant to treatment by conventional methods? If a form of liquid cannabis was available that had proven results for reducing your child’s debilitating and painful seizures by 53%, wouldn’t you obtain that medicine by whatever means possible? Here’s the only problem – it still isn’t legal in many states.